Investing.com
Published Jun 04, 2025 07:51AM ET
Inotiv, Inc. (NASDAQ:NOTV) announced that the U.S. Securities and Exchange Commission (SEC) has completed its investigation into the company's importation practices of non-human primates from Asia. According to a press release, the SEC's Division of Enforcement has decided not to recommend any enforcement action against Inotiv based on the information available as of June 2, 2025. The news comes as the company's stock has shown strong momentum, posting a 22% gain over the past week, according to InvestingPro data.
The investigation, which began with a voluntary request from the SEC in May 2023, focused on Inotiv, Envigo Global Services, Inc., and Orient BioResource Center, Inc. It examined whether their importation practices complied with the U.S. Foreign Corrupt Practices Act from December 1, 2017, to the present. The SEC issued a formal order of investigation in March 2024 and provided supplemental document requests to Inotiv in April 2024. InvestingPro analysis shows the company operates with a significant debt burden, with a debt-to-equity ratio of 2.86.
Inotiv, a company based in West Lafayette, Indiana, operates in the commercial physical and biological research sector. The company was previously known as Bioanalytical Systems Inc. before changing its name in 1997.
The conclusion of the SEC investigation without recommended enforcement action is significant for Inotiv, as it removes potential legal uncertainties surrounding its importation practices. The company's shares are traded on the Nasdaq Stock Market under the ticker symbol NOTV.
This information is based on a statement from Inotiv's 8-K filing with the SEC.
In other recent news, Inotiv Inc. reported a net loss of $0.44 per share for the second quarter of fiscal year 2025, which was better than the projected loss of $0.625 per share. The company's revenue for the quarter reached $124.3 million, marking a 4.4% increase from the previous year, although it fell slightly short of the expected $125.13 million. Notably, Inotiv's adjusted EBITDA improved significantly to $8 million, up from $3.1 million in the prior year. Jefferies analysts have responded to these developments by raising the price target for Inotiv's stock to $2.50 from $1.50, citing expectations of 20% annualized revenue growth and improved EBITDA margins. However, they maintained a Hold rating due to concerns over optimistic margin assumptions and debt maturity challenges. Inotiv's leadership team has extensive experience in gene toxicology and biotherapeutics, which Jefferies believes strengthens the company's market position. The company also settled a three-year-old litigation case for approximately $7.6 million, which contributed to the quarter's financial results. Despite these positive developments, Inotiv did not provide formal financial guidance for the rest of the fiscal year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.